Company
(symbol)#*

Date filed

Shares/units (M)

Price

Shares out@

Lead, other underwriters

Gross (US$M)

INITIAL OFFERINGS

Abivax SA (Paris; Euronext:ABVX)1

6/8/15

2S

€18.26 - €24.34

N/A

N/A

$49

Aimmune Therapeutics Inc. (Brisbane, Calif.; AIMT)

7/6/15

N/A

N/A

N/A

BofA Merrill Lynch (co-lead); Credit Suisse (co-lead); Piper Jaffray (co-lead)

$115

Altheadx Inc. (San Diego; IDGX)

12/23/14

N/A

N/A

17.9

Citigroup (co-lead); Jefferies (co-lead); William Blair; Cantor Fitzgerald

$69

Anterios Inc. (New York; ANTE)

4/2/15

3.9S

$12-$14

N/A

Stifel (co-lead); RBC Capital Markets (co-lead); JMP Securities; Needham & Co.

$50.7

Benitec Biopharma Ltd. (Balmain, Australia; BNTC)

6/24/15

ADS

N/A

N/A

N/A

$70

Biocardia Inc. (San Carlos, Calif.; BCDA)

6/16/15

N/A

N/A

N/A

Cantor Fitzgerald (co-lead); Roth Capital Partners (co-lead); Maxim Group

N/A

Clarus Therapeutics Inc. (Northbrook, Ill.; CLRS)

5/23/14

N/A

N/A

N/A

Citigroup (co-lead); Credit Suisse (co-lead); Canaccord Genuity; Needham & Co.

$86.25

Eyegate Pharma Inc. (Waltham, Mass.; OTCQB:EYEG)2

7/31/14

0.833S

$6

6.94

Aegis Capital (co-lead); Chardan Capital Markets (co-lead)

$5

Gelesis Inc. (Cambridge, Mass.; GLSS)

4/1/15

4S

$12-$14

N/A

Piper Jaffray (co-lead); Stifel (co-lead); Guggenheim Securities (co-lead)

$52

Gensight Biologics SA (Paris; GNST)

7/7/15

ADS

N/A

N/A

Leerink (co-lead); Evercore ISI (co-lead); Canaccord Genuity (co-lead)

$100

Global Blood Therapeutics Inc. (South San Francisco; GBT)

7/8/15

6S

$16-$18

N/A

Morgan Stanley (co-lead); Goldman, Sachs (co-lead); Cowen and Co.; Wedbush Pacgrow

$102

Lumena Pharmaceuticals Inc. (San Diego; LIVR)

4/2/14

N/A

N/A

N/A

Citigroup (co-lead); Cowen and Co. (co-lead); Leerink Partners (co-lead)

$75

Nabriva Therapeutics AG (Vienna; NBRV)

6/23/15

ADS

N/A

N/A

N/A

$92

Oasmia Pharmaceutical AB (Uppsala, Sweden; OASM)3

7/8/15

N/A

ADS

N/A

Ladenburg Thalmann (lead)

N/A

Oncore Biopharma Inc. (Doylestown, Pa.)4

11/25/14

N/A

N/A

N/A

N/A

N/A

Pieris Pharmaceuticals AG (Freising, Germany; PIRS)5

6/17/15

9.6S

$3.12

N/A

Oppenheimer & Co. (co-lead); JMP Securities (co-lead); Roth Capital Partners; Trout Capital

$30

Revo Biologics Inc. (Framingham, Mass.; RBIO)6

6/25/14

3.6S

$13-$15

18.4

Piper Jaffray (co-lead); Guggenheim Securities (co-lead); Roth Capital Partners; BTIG

$50.4

Silenseed Ltd. (Jerusalem; RNAI)

6/18/14

N/A

N/A

N/A

Aegis Capital (lead)

$36.4

Vtv Therapeutics Inc. (High Point, N.C.; VTVT)7

6/15/15

7.8S

$15-$17

N/A

Piper Jaffray (co-lead); Stifel, Nicolaus & Co. (co-lead); Canaccord Genuity; Janney Montgomery Scott

$172.5

Zynerba Pharmaceuticals Inc. (Devon, Pa.; ZYNE)

6/30/15

3S

$13-$15

N/A

Jefferies (co-lead); Piper Jaffray (co-lead); Canaccord Genuity; Oppenheimer & Co.

$42

Notes

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Stock symbols for companies seeking to complete IPOs are proposed.

@ This column reflects the shares outstanding following the offering, when disclosed.

N/A = Not available, applicable or reported.

The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the maximum aggregate offering price listed in the SEC filing.

This chart includes only biotech companies that develop therapeutics.

1 Abivax is seeking €44M (US$49M). An extension clause of up to 307,042 shares would push the total size of the transaction up to about €50.1M, and a further 353,098 shares are available to cover overallotments.

2 Eyegate lowered its proposed IPO size to $5M from $10M, and moved from Nasdaq to OTCQB.

3 Oasmia already trades on the Nasdaq Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX). This is its IPO on Nasdaq in the U.S.

4 Oncore Biopharma confidentially submitted a draft registration statement to the SEC for a proposed IPO.

5 Pieris plans to conduct an IPO on Nasdaq. It currently trades over the counter.

6 Revo's overallotment option: 540,000 shares.

7 Vtv Therapeutics overallotment option:1.17M common shares.